Global Dry Eye Syndrome Market Size By Type (Prescription drugs, Over-the-counter (OTC) drugs), By Application (Hospitals and Clinics, Medical Laboratories), By Region, And Segment Forecasts, 2023 to...

The Global Dry Eye Syndrome Market was valued at USD 5.1 billion in 2023 and is projected to reach USD 9.4 billion by 2031, expanding at a CAGR of 7.8% during the forecast period from 2023 to 2031. The market is primarily driven by the increasing prevalence of dry eye among aging populations, rising screen time from digital device usage, and heightened awareness of ocular health. Furthermore, advancements in treatment options, including artificial tears, anti-inflammatory drugs, and novel therapies like nasal neurostimulation, are fueling growth.

Drivers:

1. Rising Screen Time and Digital Device Usage:

Widespread use of smartphones, tablets, and computers contributes to digital eye strain, a leading cause of dry eye symptoms, particularly among younger demographics.

2. Aging Population:

Dry eye syndrome is more prevalent among individuals over the age of 50, making the global aging population a critical driver of market demand.

3. Growing Awareness of Ocular Health:

Campaigns and educational initiatives by healthcare organizations are increasing public awareness and driving the adoption of over-the-counter (OTC) and prescription treatments.

Restraints:

1. High Cost of Prescription Treatments:

While OTC products are widely available, the high cost of newer prescription medications like cyclosporine and lifitegrast limits adoption, especially in low-income regions.

2. Underdiagnosis and Misdiagnosis:

Dry eye syndrome is frequently underdiagnosed due to overlapping symptoms with other ocular conditions, which may delay appropriate treatment.

Opportunity:

1. Technological Advancements in Drug Delivery:

Emerging innovations in drug delivery systems, such as sustained-release inserts and targeted therapies, are expected to provide effective long-term relief and open new market avenues.

2. Expansion in Emerging Markets:

Increased healthcare spending and improving access to eye care in regions like Asia-Pacific and Latin America present strong growth opportunities for pharmaceutical and device manufacturers.

Market by System Type Insights:

The Artificial Tears segment held the largest share in 2023. These are the first-line treatment for most dry eye cases due to their accessibility and affordability. Meanwhile, the Prescription Drug segment, including anti-inflammatory and immunomodulatory treatments, is expected to witness the fastest growth due to better long-term efficacy.

Market by End-use Insights:

Hospitals & Clinics dominated the market in 2023, accounting for the largest revenue share. These facilities provide diagnosis and advanced treatment for severe cases of dry eye. However, Retail Pharmacies are rapidly gaining traction due to increased self-medication trends and wide product availability.

Market by Regional Insights:

North America led the global dry eye syndrome market in 2023, driven by a high prevalence of the condition, widespread healthcare access, and significant R&D investment. Asia-Pacific is anticipated to register the fastest growth rate over the forecast period, fueled by increased digital exposure, rising geriatric populations, and expanding healthcare infrastructure.

Competitive Scenario:

Major players in the global dry eye syndrome market include Allergan (AbbVie Inc.), Bausch + Lomb, Santen Pharmaceutical Co., Ltd., Johnson & Johnson Vision, Sun Pharmaceutical Industries Ltd., and Novartis AG. Key strategies include pipeline development, global expansion, and collaborations with ophthalmology specialists.

In 2023, Santen introduced a new preservative-free artificial tear formulation for sensitive eyes.

AbbVie received regulatory approval in 2024 for an enhanced cyclosporine-based treatment targeting chronic dry eye inflammation.

Bausch + Lomb expanded its manufacturing capacity in North America in 2025 to meet the growing demand for OTC eye drops.

Scope of Work – Global Dry Eye Syndrome Market

Key Market Developments:

2023: Santen Pharmaceutical launched a new preservative-free artificial tear targeting sensitive users.

2024: AbbVie obtained FDA approval for a next-gen dry eye therapy with enhanced ocular surface protection.

2025: Johnson & Johnson Vision entered a strategic partnership with a tech firm for smart contact lenses designed to monitor and alleviate dry eye symptoms.

FAQs:

1) What is the current market size of the Global Dry Eye Syndrome Market?

The market size was valued at USD 5.1 billion in 2023.

2) What is the major growth driver of the Global Dry Eye Syndrome Market?

The rising prevalence of dry eye due to increased screen time and aging populations is the major growth driver.

3) Which is the largest region during the forecast period in the Global Dry Eye Syndrome Market?

North America is projected to remain the largest region through 2031.

4) Which segment accounted for the largest market share in the Global Dry Eye Syndrome Market?

The Artificial Tears segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Dry Eye Syndrome Market?

Key players include Allergan (AbbVie), Bausch + Lomb, Santen Pharmaceutical, Johnson & Johnson Vision, and Novartis AG.